Denteric’s preclinical lead candidate GPV381 is a recombinant protein designed to restore homeostasis to the oral microbiome. Administered together with alum, it is intended to drive a specific TH2 cell immune response.
Our preclinical discovery pipeline includes investigating whether our therapies could also play a role in the prevention or treatment of Alzheimer’s disease.
Given the recent and rapid advancements in mRNA technology, Denteric is conducting a discovery program with an mRNA vaccine, supported by CRC-P funding from the Federal Government of Australia.
Currently, at a discovery stage, Denteric is developing a range of monoclonal antibodies for miscellaneous use.